Telix updates onQ4 2022 revenue update and key achievements in 2022

Telix Pharmaceuticals Limited (ASX: TLX) disclosed an unaudited revenue update for Q4 2022. The Company highlighted that it generated a revenue of AU$76.8 million from the sale of Illuccix® kit for prostate cancer imaging in the US in Q4 2022, up 39% on Q3 2022.

Besides, at the 41st Annual J.P. Morgan Healthcare Conference, the Company also talked about its key milestones in 2022. It includes:

• US$100.4 million revenue from U.S. sales of Illuccix.
• Extremely positive data from Phase III kidney cancer imaging study.
• Robust commercial performance supports change to a sustainable business.
• Buildout of organisational infrastructure to aid therapeutic pipeline development.

2023 Catalysts:

• Illuccix® - continued revenue growth and global rollout.
• Biologics License Application submission for TLX250-CDx.
• New Drug Application  for TLX101-CDx brain cancer imaging.
• Prostate cancer therapy program: ProstACT GLOBAL patient recruitment and ProstACT SELECT data readout.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com